- Home
- AARD
as 10-27-2025 9:36am EST
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 277.9M | IPO Year: | 2025 |
| Target Price: | $31.43 | AVG Volume (30 days): | 151.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.88 - $19.58 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Aardvark Therapeutics Inc. News
AARD Breaking Stock News: Dive into AARD Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek
Insider Monkey
10 days ago
Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment
MT Newswires
19 days ago
Aardvark Therapeutics Reaches Alignment With FDA on Broadening Phase 3 Prader-Willi Syndrome Trial Population
GlobeNewswire
19 days ago
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome
GlobeNewswire
4 months ago
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
Zacks
5 months ago
Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet
GlobeNewswire
5 months ago
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
GlobeNewswire
5 months ago
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
Compare AARD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AARD Aardvark Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.